Drugs / Piperacillin/tazobactam
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02795949 Comparator | Oct 2016 → Jan 2020 | bacterial infectious disease | Andalusian Public Foundation for Health Research in Seville | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Piperacillin/tazobactam | “Piperacillin/tazobactam 4/0.5 g IV/8h” NCT02795949 ↗ |
| Route | Intravenous | “Piperacillin/tazobactam 4/0.5 g IV/8h” NCT02795949 ↗ |